9PT Stock Chart & Stats
€1.07
-€0.20(-1.57%)
At close: 4:00 PM EST
€1.07
-€0.20(-1.57%)
Day’s Range― - ―
52-Week Range€0.87 - €1.63
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€61.66M
Enterprise Value€79.66M
Total Cash (Recent Filing)€170.89M
Total Debt (Recent Filing)€28.78M
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Aug 10, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.84
Shares Outstanding61,920,250
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.41
Price to Sales (P/S)0.00
P/FCF Ratio-0.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.34Price Target Upside118.51% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-1.23
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeveragePliant’s relatively low debt burden is a durable financial strength for a development-stage biotech: it lowers near-term default and interest risks, preserves access to credit or non-dilutive financing, and gives management flexibility to prioritize clinical programs without heavy fixed obligations.
Improving Cash-Burn TrendA multi-year reduction in negative free cash flow signals improving operational efficiency or better spending discipline. This trending improvement meaningfully extends runway if sustained, reducing near-term financing frequency and lowering dilution risk compared with a static or worsening burn profile.
Focused Scientific StrategyA concentrated pipeline targeting integrin biology for fibrosis provides a durable strategic advantage: deep technical focus can drive specialized expertise, clearer go-to-market positioning in underserved fibrosis indications, and potential differentiation versus broader-platform competitors if clinical validation is achieved.
Bears Say
No Commercial RevenueAbsence of product revenue is a persistent structural risk: without commercial cash flow, the company must rely on financing or partnerships to fund operations, leaving long-term viability contingent on successful trials, approvals, and commercial launches rather than operating cash generation.
Ongoing Cash Burn And Funding RelianceSustained negative cash generation creates a durable vulnerability: recurring capital raises are likely, increasing dilution risk and creating execution dependence on capital-market access. Prolonged funding needs can disrupt long-range R&D plans if market conditions tighten.
Shrinking Equity BaseA materially reduced equity base weakens the balance-sheet buffer against ongoing losses, limiting borrowing capacity and strategic flexibility. Over time this forces more frequent or larger dilutive financings and reduces resilience to trial setbacks or extended development timelines.
Pliant Therapeutics News
9PT FAQ
What was Pliant Therapeutics’s price range in the past 12 months?
Pliant Therapeutics lowest stock price was €0.87 and its highest was €1.63 in the past 12 months.
What is Pliant Therapeutics’s market cap?
Pliant Therapeutics’s market cap is €61.66M.
When is Pliant Therapeutics’s upcoming earnings report date?
Pliant Therapeutics’s upcoming earnings report date is Aug 10, 2026 which is in 31 days.
How were Pliant Therapeutics’s earnings last quarter?
Pliant Therapeutics released its earnings results on May 11, 2026. The company reported -€0.28 earnings per share for the quarter, beating the consensus estimate of -€0.312 by €0.032.
Is Pliant Therapeutics overvalued?
According to Wall Street analysts Pliant Therapeutics’s price is currently Undervalued.
Does Pliant Therapeutics pay dividends?
Pliant Therapeutics does not currently pay dividends.
What is Pliant Therapeutics’s EPS estimate?
Pliant Therapeutics’s EPS estimate is -0.3.
How many shares outstanding does Pliant Therapeutics have?
Pliant Therapeutics has 61,920,250 shares outstanding.
What happened to Pliant Therapeutics’s price movement after its last earnings report?
Pliant Therapeutics reported an EPS of -€0.28 in its last earnings report, beating expectations of -€0.312. Following the earnings report the stock price went up 0.399%.
Which hedge fund is a major shareholder of Pliant Therapeutics?
Currently, no hedge funds are holding shares in DE:9PT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pliant Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-87.90%
12-Months-Change
Fundamentals
Return on Equity
-59.06%
Trailing 12-Months
Asset Growth
-41.24%
Trailing 12-Months
Company Description
Pliant Therapeutics
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.
9PT Stock 12 Month Forecast
Average Price Target
€2.34
▲(118.51% Upside)
Technical Analysis
Options Prices
Currently, No data available
---